Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K2 | P36507 | 13/20 | 0.38 |
| ▸ | MAP2K1 | Q02750 | 13/20 | 0.38 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.36 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.36 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | ADCK1 | Q86TW2 | 1/20 | 0.36 |
| ▸ | PRKAG2 | Q9UGJ0 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CSF1R | P07333 | 1/20 | 0.33 |
| ▸ | DHODH | Q02127 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL393638 | 0.87 | MAP2K1 (0.52) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 | |
| SCHEMBL19050836 | 0.83 | MAP2K1 (0.45) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 | |
| SCHEMBL19050608 | 0.82 | MAP2K2 (0.39) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 | |
| SCHEMBL14263851 | 0.82 | MAP2K2 (0.40) | MAP2K2MAP2K1MEN1MAPK1KMT2A | |
| SCHEMBL19050852 | 0.80 | MAP2K1 (0.60) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 | |
| SCHEMBL19050691 | 0.80 | MAP2K1 (0.60) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 | |
| SCHEMBL19050680 | 0.80 | MAP2K1 (0.60) | MAP2K2MAP2K1CHEK1MAPK10PRKAG1 | |
| SCHEMBL391647 | 0.79 | MRGPRX1 (0.44) | MAP2K2MAP2K1MEN1MAPK1KMT2A | |
| SCHEMBL19050687 | 0.79 | MAP2K2 (0.38) | MAP2K2MAP2K1MEN1MAPK1KMT2A | |
| SCHEMBL19050839 | 0.79 | ACLY (0.42) | MAP2K2MAP2K1MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MAP2K2 48/4885MAP2K1 52/4885CHEK1 260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.